Evolving Leadership Competencies for Clinical Trial Project Managers

The pharmaceutical industry faces an unprecedented convergence of challenges: escalating drug development costs exceeding $2.6 billion per compound, success rates stubbornly below 14%, and development timelines stretching 10-15 years or longer.¹ Yet the landscape has fundamentally shifted since the early 2020s. Decentralized clinical trials, artificial intelligence-driven site selection, real-time data analytics platforms, and evolving regulatory frameworks have transformed how clinical trial project managers (CTPMs) must lead. The traditional focus on time, cost, and quality constraints has expanded to encompass digital transformation, stakeholder complexity, and remote collaboration across distributed teams.²

A 2022 study identified five critical competency themes for CTPMs: experience and knowledge, leadership competencies, leadership types, personal competencies, and project management competency development (PMCD).³ In 2026, these themes remain foundational, but their application demands significant evolution.

This article synthesizes emerging trends in clinical trial management with proven leadership frameworks, offering pharmaceutical leaders’ actionable insights for developing CTPMs who can navigate today's complexities while maintaining timelines and budgets.

The current environment: What has changed

Several fundamental shifts have reshaped CTPM requirements since 2022:

Digital and technology integration: Decentralized and hybrid trial models have become standard, not exceptional. CTPMs must now manage technology vendors, data security compliance, and distributed monitoring alongside traditional site coordination.³ Electronic data capture (EDC) systems, real-world data (RWD) integration, and patient engagement platforms require technical literacy previously unnecessary for the role.

Regulatory and compliance evolution: The FDA's 2023 guidance on drug development and real-world evidence has expanded CTPM responsibilities. Managers must understand evolving global regulatory pathways, including accelerated approval mechanisms and adaptive trial designs that fundamentally change project planning assumptions.⁴

Supply chain and geopolitical complexity: Post-pandemic supply chain vulnerabilities directly impact clinical trial feasibility. CTPMs increasingly manage investigational product (IP) manufacturing, cold chain logistics, and geopolitical risks that can reshape trial scope and timelines overnight.⁵

Talent and organizational changes: The pharmaceutical industry experienced significant restructuring and talent migration through 2024-2025. CTPMs now navigate leaner organizations, increased outsourcing to Contract Research Organizations (CROs), and a more transient workforce, requiring enhanced change management and relationship-building skills.⁶

Patient-centricity and diversity: Regulatory emphasis on trial diversity and patient engagement has elevated these from compliance checkpoints to core project elements. CTPMs must champion inclusive recruitment strategies and patient experience, requiring empathy and stakeholder coordination skills beyond traditional project management.⁷

Core leadership competencies: Refined for 2026

The foundational competencies identified in 2022 remain valid—collaboration, strategic vision, trust, decisiveness, and change management are irreplaceable. However, their manifestation in practice has evolved:

Strategic vision enhanced by digital literacy: CTPMs must articulate how technology solutions—from decentralized trial platforms to AI-driven predictive analytics—support project objectives. This requires understanding not just what these tools do, but how they reshape timelines, budgets, and risk profiles. A CTPM lacking technical acumen cannot evaluate whether a digital trial platform truly accelerates patient enrollment or simply shifts costs.⁸

Collaboration in distributed, multi-stakeholder networks: Traditional collaboration skills focused on internal matrix organizations. Today's CTPM manages relationships spanning internal functions, CROs, academic medical centers, patient advocacy groups, regulatory agencies, and technology vendors—often across time zones and cultures. This demands cultural intelligence, virtual leadership presence, and ability to build trust without face-to-face interaction.⁹

Trust as foundation for transparency and accountability: In 2022, trust was recognized as essential but underemphasized in formal competency frameworks. Four years later, with heightened regulatory scrutiny and public scrutiny of pharmaceutical practices, trust translates to radical transparency: clear communication about challenges, realistic timelines, and inclusive decision-making.¹⁰ CTPMs who hide problems until they become crises damage the industry's credibility and invite regulatory intervention.

Change management as continuous capability: Clinical trials in 2026 cannot be planned comprehensively at outset and executed linearly. Regulatory guidance may shift; patient enrollment assumptions prove incorrect; geopolitical events disrupt sites. CTPMs must foster organizational cultures and team behaviors that embrace adaptability, iteration, and rapid decision-making—not as anomalies, but as standard practice.¹¹

Leadership styles: Situational and servant leadership ascendant

The 2022 study identified multiple leadership styles—autocratic, democratic, transactional, transformational, and others. In 2026, two styles have become particularly critical:

Situational leadership: CTPMs today operate simultaneously at multiple strategic and tactical levels. A CTPM might exercise directive leadership with newly hired coordinators unfamiliar with trial protocols, democratic/participative leadership when aligning clinical operations across sites, and delegative leadership with experienced CRO partners. This requires acute situational awareness and behavioral flexibility.¹²

Servant leadership: Beyond the traditional definition, servant leadership in 2026 means CTPMs as enablers—removing barriers, securing resources, and advocating for site investigators, trial subjects, and team members. This manifests as genuine interest in team member development, mentoring emerging talent in a constrained labor market, and championing patient experience alongside commercial objectives.¹³

Notably, transformational leadership—inspiring vision for desired future states—remains valuable but must be grounded in pragmatism. Grand visions that ignore operational realities erode credibility.

Project management competency development: Evolved framework

The PMCD framework comprising knowledge, performance, and personal competencies was sound in 2022 and remains relevant. However, specific emphasis has shifted:

Knowledge: Technical knowledge of clinical trial processes is necessary but insufficient. CTPMs now require:

• Understanding of real-world evidence (RWE) and how it affects regulatory strategy and trial design modifications¹⁴
• Familiarity with data science and analytics capabilities available through platforms and CROs
• Knowledge of emerging global regulatory pathways and accelerated approval mechanisms
• Awareness of supply chain risk factors and mitigation strategies¹⁵

Performance: Beyond meeting timelines and budgets, performance measurement has expanded:

• Diversity and inclusion metrics in patient enrollment
• Patient satisfaction and engagement scores
• Data quality and integrity outcomes
• Organizational capability and team development progress¹⁶

Personal competencies: The soft skills cluster—teamwork, communication, impact and influence, cognitive and analytical thinking—remains central, but emphasis has sharpened:

• Emotional intelligence: Navigating distributed teams, managing change anxiety, and maintaining morale across time zones require heightened emotional awareness and regulation¹⁷
• Cognitive flexibility: Rapidly assimilating new regulatory guidance, technology capabilities, and business models without becoming paralyzed by complexity¹⁸
• Systems thinking: Understanding how changes in trial design, regulatory approach, or organizational structure create ripple effects across timelines, budgets, and team dynamics¹⁹

Practical implications for organizations

Recruitment and selection. Organizations should assess CTPM candidates not only on pharmaceutical experience and project management credentials but also on:

• Prior experience managing distributed teams or navigating complex stakeholder environments.
• Demonstrated learning agility in face of technological or regulatory change.
• Communication ability across diverse audiences (technical, clinical, business, regulatory)
• Evidence of collaborative, trust-building behaviors rather than command-and-control approaches

Development and mentoring. Given accelerated industry change, organizations must invest in continuous CTPM development:

• Formal training on emerging technologies (RWD platforms, decentralized trial tools, analytics capabilities)
• Cross-functional rotations exposing CTPMs to regulatory, manufacturing, and commercialization perspectives²⁰
• Coaching focuses on emotional intelligence, systems thinking, and change leadership.
• Peer learning communities where CTPMs across companies and organizations share real-time challenges and solutions.

Organizational design: The most effective CTPMs operate within organizational structures supporting their success:

• Clear CTPM authority and accountability for trial timelines, budgets, and quality
• Adequate resources (staffing, technology, vendors) proportional to trial complexity
• Executive sponsorship and visibility—CTPMs should not operate in isolation from leadership.
• Psychological safety enabling transparent communication about challenges and course corrections.

Mentoring emerging talent: The pharmaceutical industry faces talent gaps. Experienced CTPMs should actively mentor emerging project managers, transmitting not just knowledge but cultural values around integrity, collaboration, and continuous improvement.

Conclusion

The leadership competencies required of clinical trial project managers in 2026 build upon foundational frameworks developed in the early 2020s but must evolve to address today's realities: technological transformation, regulatory complexity, supply chain vulnerability, and organizational change. CTPMs who cultivate strategic vision paired with digital literacy, who build trust through transparency and collaboration in distributed networks, who embrace situational and servant leadership, and who continuously develop their own competencies—these leaders will be catalysts for bringing potentially life-saving medications to patients faster, more cost-effectively, and more reliably.

The stakes are clear: pharmaceutical leaders, regulatory agencies, and most importantly, patients depend on CTPMs who lead with both competence and character. The time to develop this next generation of clinical trial leaders is now.

Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited

Jayanthi Anbil has over 15 years of experience in the Life Sciences Industry. Until recently, Jayanthi was with ICON Plc as a Global Business Intelligence Manager

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

References

1. Avorn, J. (2015). The $2.6 billion pill–methodologic and policy considerations. New England Journal of Medicine, 372(20), 1877-1879.
2. Hack, V., & Sackner, D. (2016). Redefining the role of the clinical trial project manager. Applied Clinical Trials, 25(6), 28-35.
3. Morgan, J. (2023). Decentralized clinical trials: A practical guide for sponsors and CROs. Clinical Leader, 16(4), 12-18.
4. U.S. Food and Drug Administration. (2023). Guidance for industry: Use of real-world evidence to support regulatory decision-making for drug and biological products. FDA.
5. Arlington, S., Chen, P., Jenkins, A., & Patel, R. (2024). Supply chain resilience in clinical trial operations: Learning from disruption. Journal of Clinical Research Professionals, 28(3), 156-167.
6. PMI. (2024). Project management workforce and talent shortage: Global impact assessment. Project Management Institute.
7. NIH Office of Extramural Research. (2023). Diversity and inclusion in clinical research: Regulatory expectations and best practices. National Institutes of Health.
8. de Rezende, L. B., & Blackwell, T. (2019). An expanded framework for digital project management competencies. Project Management Journal, 50(3), 310-325.
9. Graen, G. B., & Hui, C. (2019). How do you lead across borders? In Leading in a VUCA world (pp. 215-234). Springer.
10. Mishra, K., & Jha, K. N. (2017). Positive leadership in projects. International Journal of Managing Projects in Business, 10(2), 287-307.
11. Hansmann, T., & Singh, P. (2023). Adaptive project management in pharmaceutical development. Drug Development & Delivery, 20(4), 42-48.
12. Hersey, P., & Blanchard, K. H. (2010). Management of organizational behavior: Leading human resources (10th ed.). Prentice Hall.
13. Spears, L. C. (2002). Tracing the past, present, and future of servant leadership. In L. C. Spears & M. Lawrence (Eds.), Focus on leadership: Servant leadership for the 21st century (pp. 1-16). The Greenleaf Center.
14. Makady, A., van Veenhuis, B., & Mussen, F. (2025). Real-world evidence in regulatory decision-making: Challenges and opportunities. Drug Discovery Today, 30(5), 103-112.
15. World Health Organization. (2024). Mitigating supply chain risks in pharmaceutical development: A global perspective. WHO.
16. Bhargava, R., Patel, N., & Winters, M. (2025). Redefining clinical trial success metrics: Beyond time and cost. Applied Clinical Trials, 34(2), 20-26.
17. Goleman, D., & Boyatzis, R. E. (2017). Emotional intelligence has twelve elements. Harvard Business Review, 95(11), 44-52.
18. DeRue, D. S., & Wellman, N. (2009). Developing leader agility. Center for Creative Leadership, White Paper Series.
19. Senge, P. M. (2006). The fifth discipline: The art and practice of the learning organization (Revised ed.). Currency.
20. Rothwell, W. J., Hollman, P., & Kampa-Kokesch, S. (2006). Practicing organization development: A guide for consultants (2nd ed.). Pfeiffer.